Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1985 Feb;84(2):561-71.
doi: 10.1111/j.1476-5381.1985.tb12941.x.

An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation

Comparative Study

An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation

J W Black et al. Br J Pharmacol. 1985 Feb.

Abstract

An operational model of pharmacological agonism has been analysed to predict the behaviour of rectangular hyperbolic and non-hyperbolic agonist-concentration effect, E/[A], curves with variation in receptor concentration, [Ro]. Irreversible antagonism is predicted to cause E/[A] curve gradient changes in non-hyperbolic cases but not in hyperbolic cases; in both cases estimation of agonist dissociation constants (KAS) is theoretically valid. 5-Hydroxytryptamine (5-HT) produced "steep' E/[A] curves in contracting the rabbit isolated aorta preparation. Irreversible antagonism by phenoxybenzamine (Pbz) produced a flattened E/[A] curve, consistent with theoretical predictions. Fitting 5-HT E/[A] curves in the presence and absence of Pbz to the model provided an estimate of KA for 5-HT which was not significantly different from the estimate obtained using Furchgott's null method. The operational model of agonism appears to account qualitatively and quantitatively for the effects of [Ro] changes on hyperbolic and non-hyperbolic E/[A] curves. Under conditions where irreversible antagonism may be used to estimate KAS, fitting the operational model directly to E/[A] data represents a valid, economical and analytically simple alternative to the conventional null method.

PubMed Disclaimer

References

    1. J Pharm Pharmacol. 1981 Nov;33(11):715-9 - PubMed
    1. Br J Pharmacol. 1976 Oct;58(2):211-21 - PubMed
    1. Proc R Soc Lond B Biol Sci. 1983 Dec 22;220(1219):141-62 - PubMed
    1. J Pharmacol Methods. 1983 Dec;10(4):231-41 - PubMed
    1. Br J Pharmacol. 1984 Jun;82(2):501-8 - PubMed

Publication types